Inventor · disambiguated record
Maria Fardis
Also filed as: FARDIS MARIA
26 granted patents·46 pending applications·572 citations·filing 2001–2025
97Inventor score
Files withIOVANCE BIOTHERAPEUTICS INC29GILEAD SCIENCES INC18BOOJAMRA CONSTANTINE G4CANNIZZARO CARINA3CHEN JAMES M3
Top patents by PatentIndex Score
72 records- 0198US11819517B2Methods of using tumor infiltrating lymphocytes in double-refractory melanomaIOVANCE BIOTHERAPEUTICS INC·Filed 2018·Granted Nov 21, 2023·18 cites·15 claims
- 0298US11433097B2Methods of using tumor infiltrating lymphocytes in double-refractory melanomaIOVANCE BIOTHERAPEUTICS INC·Filed 2018·Granted Sep 6, 2022·25 cites·23 claims
- 0397US9139604B2Antiviral phosphonate analogsGILEAD SCIENCES INC·Filed 2014·Granted Sep 22, 2015·42 cites·9 claims
- 0497US8871785B2Antiviral phosphonate analogsGILEAD SCIENCES INC·Filed 2013·Granted Oct 28, 2014·49 cites·23 claims
- 0597US7645747B2Therapeutic phosphonate compoundsGILEAD SCIENCES INC·Filed 2005·Granted Jan 12, 2010·60 cites·29 claims
- 0696US8022083B2Antiviral phosphonate analogsGILEAD SCIENCES INC·Filed 2008·Granted Sep 20, 2011·46 cites·29 claims
- 0796US7452901B2Anti-cancer phosphonate analogsGILEAD SCIENCES INC·Filed 2004·Granted Nov 18, 2008·70 cites·13 claims
- 0890US7417055B2Kinase inhibitory phosphonate analogsGILEAD SCIENCES INC·Filed 2004·Granted Aug 26, 2008·37 cites·14 claims
- 0990US7407965B2Phosphonate analogs for treating metabolic diseasesGILEAD SCIENCES INC·Filed 2004·Granted Aug 5, 2008·27 cites·12 claims
- 1089US7893264B2Antiviral phosphinate compoundsGILEAD SCIENCES INC·Filed 2007·Granted Feb 22, 2011·15 cites·47 claims
- 1189US7649015B2Cellular accumulation of phosphonate analogs of HIV protease inhibitor compoundsGILEAD SCIENCES INC·Filed 2003·Granted Jan 19, 2010·19 cites·11 claims
- 1289US7432261B2Anti-inflammatory phosphonate compoundsGILEAD SCIENCES INC·Filed 2004·Granted Oct 7, 2008·24 cites·20 claims
- 1389US7429565B2Antiviral phosphonate analogsGILEAD SCIENCES INC·Filed 2004·Granted Sep 30, 2008·25 cites·20 claims
- 1489US6624302B2Polyketide derivativesKOSAN BIOSCIENCES INC·Filed 2002·Granted Sep 23, 2003·19 cites·12 claims
- 1588US7470724B2Phosphonate compounds having immuno-modulatory activityGILEAD SCIENCES INC·Filed 2004·Granted Dec 30, 2008·23 cites·20 claims
- 1688US7427636B2Inosine monophosphate dehydrogenase inhibitory phosphonate compoundsGILEAD SCIENCES INC·Filed 2004·Granted Sep 23, 2008·21 cites·18 claims
- 1787US2024392245A1Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereofIOVANCE BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1886US12343380B2Expansion of TILs utilizing AKT pathways inhibitorsIOVANCE BIOTHERAPEUTICS INC·Filed 2019·Granted Jul 1, 2025·2 cites·28 claims
- 1986US7253180B2Pre-organized tricyclic integrase inhibitor compoundsGILEAD SCIENCES INC·Filed 2003·Granted Aug 7, 2007·17 cites·66 claims
- 2085US2023414662A1Methods of using tumor infiltrating lymphocytes in double-refractory melanomaIOVANCE BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2183US2023340412A1Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral BloodIOVANCE BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2282US7427624B2Purine nucleoside phosphorylase inhibitory phosphonate compoundsGILEAD SCIENCES INC·Filed 2004·Granted Sep 23, 2008·12 cites·18 claims
- 2382US2025336497A1Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereofIOVANCE BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2481US7432273B2Phosphonate analogs of antimetabolitesGILEAD SCIENCES INC·Filed 2004·Granted Oct 7, 2008·9 cites·8 claims
- 2580US2023092130A1Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereofIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2678US6569867B2Polyketide derivativesKOSAN BIOSCIENCES INC·Filed 2001·Granted May 27, 2003·6 cites·28 claims
- 2778US2025243458A1Methods of using tumor infiltrating lymphocytes in double-refractory melanomaIOVANCE BIOTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2876US2024390424A1Cytokine associated tumor infiltrating lymphocytes compositions and methodsIOVANCE BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2976US2024408136A1Cytokine associated tumor infiltrating lymphocytes compositions and methodsIOVANCE BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3074US2024325446A1Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitorsIOVANCE BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3174US2025017971A1Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitorsIOVANCE BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3273US2020347350A1Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral BloodIOVANCE BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3371US2023374453A1Treatment of nsclc patients with tumor infiltrating lymphocyte therapiesIOVANCE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3471US2024307450A1Treatment of nsclc patients refractory for anti-pd-1 antibodyIOVANCE BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3571US2020224161A1Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereofIOVANCE BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3671US2023372397A1Treatment of nsclc patients with tumor infiltrating lymphocyte therapiesIOVANCE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3770US7125844B2Dab9 derivatives of lipopeptide antibiotics and methods of making and using the sameMIGENIX INC·Filed 2003·Granted Oct 24, 2006·4 cites·25 claims
- 3869US2009227543A1Phosphonate compounds having immuno-modulatory activityCANNIZZARO CARINA·Filed 2008·Application pending·0 cites
- 3967US2024307437A1Cytokine associated tumor infiltrating lymphocytes compositions and methodsIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4064US7432272B2Antiviral analogsGILEAD SCIENCES INC·Filed 2004·Granted Oct 7, 2008·2 cites·27 claims
- 4164US2021369775A1Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereofIOVANCE BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4264US2024299539A1Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitorsIOVANCE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4363US2009156558A1Phosphonate analogs of antimetabolitesFARDIS MARIA·Filed 2008·Application pending·0 cites
- 4461US2025101380A1Tumor infiltrating lymphocytes engineered to express payloadsIOVANCE BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4560US2025099588A1Cytokine associated tumor infiltrating lymphocytes compositions and methodsIOVANCE BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4659US2024131064A1Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitorsIOVANCE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4759US2024123067A1Treatment of cancers with tumor infiltrating lymphocyte therapiesIOVANCE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4859US2022118012A1Treatment of nsclc patients refractory for anti-pd-1 antibodyIOVANCE BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4958US2009181930A1Kinase inhibitory phosphonate analogsCANNIZZARO CARINA·Filed 2008·Application pending·0 cites
- 5057US7655623B2Dab9 derivatives of lipopeptide antibiotics and methods of making and using the sameMIGENIX INC·Filed 2006·Granted Feb 2, 2010·0 cites·8 claims
Showing the top 50 of 72 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Maria Fardis files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →